Q: Do you have a target exit value or some recent comps you can share?

A: We have in mind an exit of over $200M based on Organon's purchase of Alydia (JADA system for postpartum hemorrhage) for $240M in 2021. King Lee thinks $300M is a good possibility—especially given the three large markets we address. See slide 17--third slide after the Appendices slide.

Postpartum hemorrhage is a serious condition and the drugs usually work very well. An OB/Gyn might need a device like this once a year or so--when the drugs don't work--so it is a very small market (compared to Coologics' three larger markets).  JADA has huge implications for developing countries that lack access to IV's, medications, and transfusions. Organon also agreed to buy Fornendo for over $954M for a drug that ultimately failed its Phase II trial.

Organon sold this JADA to Laborie for $464 M in 2025. Laborie, Organon, Hologic, Cooper Surgical, Bayer (Rx), and three OTC companies (Kimberly Clark, Church and Dwight, and Foundation Consumer HC) are other potential exits. Our CCO is formerly of Organon and sees huge potential with them since their products use the same sales vertical as Coologics. And, we have had multiple interactions with Laborie. Foundation is reviewing the opportunity now.

In any case, we hope to exit within the next 18-24 months.

Trial Updates

The trial has 42 eligible patients (must have positive fungal cultures) out of the 49 needed. However, only 20-25% of the data has been analyzed primarily because we had to hire outside consultants to review the data, as the CRO's MD reviewer has serious health issues.

Not all of the existing 42 will end up in the final analysis (depending on dropout rates or exclusion criteria that are not known immediately). I am not allowed access to the data, as that may risk a finding of bias by the FDA. The only data I have access to are the microbiology results showing fungal culture results and other information, such as STIs. This is how I know that 42 are potentially eligible for the final analysis.

Our consultant data reviewer and statistician tells me we are trending in the right direction. Anything over 50% efficacy is considered statistically significant, and the last two drugs cleared by the FDA were only 50% effective at V2 or Visit 2.

Right now, we show 91% (10/11) success with no rescue medication before V2, and 75% (8/11) success with no rescue medication before V3. No rescue medication is the true barometer of clinical efficacy because we do not do VSS scores in clinical practice. Failed efficacy occurs when they require another medication.

For us, of those that failed the primary endpoint of VSS=0 at V2, 75% (3/4) of those had a greater than 50% reduction in VSS scores (secondary endpoint). For V3, 100% had greater than 50% reduction in VSS scores (secondary endpoint). None of those required a rescue medication, either.

Patent Updates

Regarding the patents, attached are the two granted patents (Kim 001 and Kim 002). Kim 002 is the Method and good until 2034. There have been more office actions to expand the claims. Kim 003 (application attached) is pending for preterm birth and other indications. It was filed 7 years later than Kim 001 /002, so once granted, it will be effective for much longer.